Influence of RANTES, SDF-1 and TGF-β levels on the value of interleukin-7 as a predictor of virological response in HIV-1-infected patients receiving double boosted protease inhibitor-based therapy

HIV Medicine

Volumn 6, Issue 4, 2005, Pages 268-277

  Boulassel, M R ^a,b   Smith, G H R ^a   Edwardes, M D deB ^b   Young, M ^a   Klein, M ^a   Gilmore, N ^a   MacLeod, J ^a   LeBlanc, R ^a   Rene P ^a   Allan, J ^a   Lalonde, R G ^a   Routy, Jean Pierre ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

HIV 1 infection; IL 7; Predictive value; RANTES; SDF 1; TGF

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; INTERLEUKIN 7; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; RANTES; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STROMAL CELL DERIVED FACTOR 1; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; T LYMPHOCYTE;

ADULT; AGED; CD4 LYMPHOCYTE COUNT; CHEMOKINES, CXC; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INTERLEUKIN-7; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROTEASE INHIBITORS; RANTES; TRANSFORMING GROWTH FACTOR BETA; VIRAL LOAD;

EID: 22644439372     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2005.00306.x     Document Type: Article

References (33)

1. Lawn SD, Butera ST, Folks TM. Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection. Clin Microbiol Rev 2001; 14: 753-777.
2. Hunt PW, Deeks SG, Rodriguez B et al. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS 2003; 17: 1907-1915.
3. Tarwater PM, Margolick JB, Jin J et al. Increase and plateau of CD4 T-cell counts in the 3(1/2) years after initiation of potent antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 27: 168-175.
4. Notermans DW, Pakker NG, Hamann D et al. Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated human immunodeficiency virus type 1-infected adults. J Infect Dis 1999; 180: 1050-1056.
5. Boulassel MR, Smith GH, Gilmore N et al. Interleukin-7 levels may predict virological response in advanced HIV-1-infected patients receiving lopinavir/ritonavir-based therapy. HIV Med 2003; 4: 315-320.
6. Fry TJ, Connick E, Falloon J et al. A potential role for interleukin-7 in T-cell homeostasis. Blood 2001; 97: 2983-2990.
7. Napolitano LA, Grant RM, Deeks SG et al. Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis. Nat Med 2001; 7: 73-79.
8. Llano A, Barretina J, Gutierrez A, Clotet B, Este JA. Interleukin-7-dependent production of RANTES that correlates with human immunodeficiency virus disease progression. J Virol 2003; 77: 4389-4395.
9. Dragic T. An overview of the determinants of CCR5 and CXCR4 co-receptor function. J Gen Virol 2001; 82: 1807-1814.
10. Aukrust P, Muller F, Froland SS. Circulating levels of RANTES in human immunodeficiency virus type 1 infection: effect of potent antiretroviral therapy. J Infect Dis 1998; 177: 1091-1096.
11. Paxton WA, Martin SR, Tse D et al. Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure. Nat Med 1996; 2: 412-417.
12. Zagury D, Lachgar A, Chams V et al. C-C chemokines, pivotal in protection against HIV type 1 infection. Proc Natl Acad Sci USA 1998; 95: 3857-3861.
13. Polo S, Veglia F, Malnati MS et al. Longitudinal analysis of serum chemokine levels in the course of HIV-1 infection. AIDS 1999; 13: 447-454.
14. Kreuzer KA, Rockstroh JK, Kupfer B, Spengler U. Endogenous levels of C-C chemokines MIP-1 alpha, MIP-1beta, and RANTES do not reflect the disease course in HIV-seropositive individuals. Int J Clin Lab Res 2000; 30: 163-168.
15. McKenzie SW, Dallalio G, North M, Frame P, Means RT Jr. Serum chemokine levels in patients with non-progressing HIV infection. AIDS 1996; 10: F29-F33.
16. Ye P, Kazanjian P, Kunkel SL, Kirschner DE. Lack of good correlation of serum CC-chemokine levels with human immunodeficiency virus-1 disease stage and response to treatment. J Lab Clin Med 2004; 143: 310-319.
17. Soriano A, Martinez C, Garcia F et al. Plasma stromal cell-derived factor (SDF)-1 levels, SDF1-3′A genotype, and expression of CXCR4 on T lymphocytes: Their impact on resistance to human immunodeficiency virus type 1 infection and its progression. J Infect Dis 2002; 186: 922-931.
18. Llano A, Barretina J, Blanco J, Gutierrez A, Clotet B, Este JA. Stromal-cell-derived factor 1 prevents the emergence of the syncytium-inducing phenotype of HIV-1 in vivo. AIDS 2001; 15: 1890-1892.
19. Derdeyn CA, Costello C, Kilby JM, Sfakianos G, Saag MS, Kaslow R, Bucy RP. Correlation between circulating stromal cell-derived factor 1 levels and CD4 + cell count in human immunodeficiency virus type 1-infected individuals. AIDS Res Hum Retroviruses 1999; 15: 1063-1071.
20. Villalba S, Salvucci O, Aoki Y et al. Serum inactivation contributes to the failure of stromal-derived factor-1 to block HIV-I infection in vivo. J Leukoc Biol 2003; 74: 880-888.
21. Llano A, Barretina J, Gutierrez A et al. Interleukin-7 in plasma correlates with CD4 T-cell depletion and may be associated with emergence of syncytium-inducing variants in human immunodeficiency virus type 1-positive individuals. J Virol 2001; 75: 10319-10325.
22. Kinter A, Catanzaro A, Monaco J et al. CC-chemokines enhance the replication of T-tropic strains of HIV-1 in CD4( + ) T cells: Role of signal transduction. Proc Natl Acad Sci USA 1998; 95: 11880-11885.
23. Kekow J, Wachsman W, McCutchan JA et al. Transforming growth factor-beta and suppression of humoral immune responses in HIV infection. J Clin Invest 1991; 87: 1010-1016.
24. Li JM, Shen X, Hu PP, Wang XF. Transforming growth factor beta stimulates the human immunodeficiency virus 1 enhancer and requires NF-kappaB activity. Mol Cell Biol 1998; 18: 110-121.
25. Havlir DV, Torriani FJ, Schrier RD et al. Serum interleukin-6 (IL-6), IL-10, tumor necrosis factor (TNF) alpha, soluble type II TNF receptor, and transforming growth factor beta levels in human immunodeficiency virus type 1-infected individuals with Mycobacterium avium complex disease. J Clin Microbiol 2001; 39: 298-303.
26. Perrella O, Carreiri PB, Perrella A et al. Transforming growth factor beta-1 and interferon-alpha in the AIDS dementia complex (ADC): Possible relationship with cerebral viral load? Eur Cytokine Netw 2001; 12: 51-55.
27. Barcellini W, Rizzardi GP, Poli G et al. Cytokines and soluble receptor changes in the transition from primary to early chronic HIV type 1 infection. AIDS Res Hum Retroviruses 1996; 12: 325-331.
28. Routy JP, Vanhems P, Rouleau D et al. Comparison of clinical features of acute HIV-1 infection in patients infected sexually or through injection drug use. J Acquir Immune Defic Syndr 2000; 24: 425-432.
29. Boulassel MR, Spurll G, Rouleau D et al. Changes in immunological and virological parameters in HIV-1 infected subjects following leukapheresis. J Clin Apheresis 2003; 18: 55-60.
30. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8 + T cells. Science 1995; 270: 1811-1815.
31. Letterio JJ, Roberts AB. Regulation of immune responses by TGF-beta. Annu Rev Immunol 1998; 16: 137-161.
32. Lee G, Namen AE, Gillis S, Ellingsworth LR, Kincade PW. Normal B cell precursors responsive to recombinant murine IL-7 and inhibition of IL-7 activity by transforming growth factor-beta. J Immunol 1989; 142: 3875-3883.
33. Tang J, Nuccie BL, Ritterman I, Liesveld JL, Abboud CN, Ryan DH. TGF-beta down-regulates stromal IL-7 secretion and inhibits proliferation of human B cell precursors. J Immunol 1997; 159: 117-125.